<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235131</url>
  </required_header>
  <id_info>
    <org_study_id>EE04-02</org_study_id>
    <nct_id>NCT00235131</nct_id>
  </id_info>
  <brief_title>The Study to Compare the Cordis SMART™ Stent System With the Bard® Luminexx™ Stent</brief_title>
  <acronym>SUPER SL</acronym>
  <official_title>A Clinical Investigation of the Cordis S.M.A.R.T. ™ CONTROL ™ Nitinol Stent System Versus the Bard® Luminexx™ 6F Vascular Stent for the Treatment of TASC C &amp; D Superficial Femoral Artery Long Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the performance of the Cordis S.M.A.R.T.™ CONTROL ™ Nitinol Stent
      System for the treatment of TASC C &amp; D superficial femoral artery long lesions (up to 22 cm)
      in comparison with the Bard® Luminexx™ 6F Vascular Stent as determined by the primary patency
      rate at 6 and 12 months post procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a German multi-center prospective, randomized, two-arm study evaluating performance
      of the Cordis S.M.A.R.T.™ CONTROL ™ Nitinol Stent System as compared to the C.R. Bard®
      Luminexx™ 6F Vascular Stent. Patients will be randomized on a 1:1 basis. It is anticipated
      that a total of 200 patients will be entered into the study.

      The study population will consist of approximately 200 symptomatic peripheral vascular
      disease patients with TASC C &amp; D SFA lesions. The disease will consist of symptomatic, long
      de novo or restenotic lesions (&gt; 70% stenosis) and occlusions (5 - 22 cm) on diagnostic
      imaging. The lesion must not extend into the distal SFA and the popliteal artery. At least
      one distal popliteal artery must be patent as well as one calf vessel. Reference vessel
      diameter must be &gt;= 4.0 to &lt;= 6.0 mm.

      Trial participants will be randomized to the Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
      or to the Bard® Luminexx™ 6F Vascular Stent.

      Patients will be followed for twelve months post-procedure. Study examinations will be done
      at screening, procedure time, discharge, six, and twelve months post procedure.

      This study will be conducted over up to 15 investigational sites in Germany.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary patency detectable by duplex ultrasound through the index lesion</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>technical success</measure>
    <time_frame>time of deployment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedural success</measure>
    <time_frame>up to removal of catheter sheath</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedural complications</measure>
    <time_frame>up to removal of catheter sheath</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle Brachial Index</measure>
    <time_frame>discharge and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>primary patency</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>binary restenosis</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent fractures</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularisation</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularisation</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>baseline, discharge, 6 and 12 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical categorization of chronic limb ischemia by means of the Rutherford classification</measure>
    <time_frame>discharge, 6 and 12 months post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bard® Luminexx™ 6F Vascular Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Smart Stent</intervention_name>
    <description>Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Luminexx Stent</intervention_name>
    <description>Bard® Luminexx™ 6F Vascular Stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic leg ischemia by Rutherford classification (category 2, 3, 4 or 5);
             duration of intermittent claudication (category 2-3) should be at least 3 months.

          -  One superficial femoral artery de novo or restenotic lesion (more than 70% stenosis or
             occlusions), with a lesion length of more than 5 to less than 22 cm.

          -  Patent popliteal artery on the index side, i.e., single vessel runoff or better with
             at least one of three vessels patent to the lower 1/3 of the calf prior to the day of
             the procedure.

        Exclusion Criteria:

          -  Revascularisation involving the same limb within 30 days prior to the index procedure
             or a planned revascularisation within 30 days after the index procedure.

          -  Patients having total occlusions of the iliac artery on the same side must be
             excluded.

          -  Previously implanted stent(s) in the to be treated artery at the same site.

          -  Requiring stent placement in the distal superficial femoral artery and the popliteal
             artery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dierk Schneinert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Duda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gemeinschaftspraxis füsar Radiologische</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis füsar Radiologische Diagnostik&amp; Zentrum für Minimal Invasite Therapie am Jüdischen Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Leipzig Herzzentrum Abt. Für Klinische u. Intervent. Angiologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <keyword>Peripheral Artery Occlusive Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

